

HR 7953

To accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing a reciprocal approval mechanism with trusted international regulatory authorities.

Congress: 119 (2025–2027, Current)

Chamber: House

Introduced: Mar 17, 2026

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 17, 2026)

Official Text: <https://www.congress.gov/bill/119th-congress/house-bill/7953>

Sponsor

Name: Rep. Sessions, Pete [R-TX-17]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Peters, Scott H. [D-CA-50]	D · CA		Mar 17, 2026

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 17, 2026

Subjects & Policy Tags

No subjects or policy tags are listed for this bill.

Related Bills

No related bills are listed.

Summary

No summary is currently available for this bill.

Actions Timeline

- **Mar 17, 2026:** Introduced in House
- **Mar 17, 2026:** Introduced in House
- **Mar 17, 2026:** Referred to the House Committee on Energy and Commerce.